167 related articles for article (PubMed ID: 8395133)
1. Drug resistance associated with altered DNA topoisomerase II.
Beck WT; Danks MK; Wolverton JS; Kim R; Chen M
Adv Enzyme Regul; 1993; 33():113-27. PubMed ID: 8395133
[No Abstract] [Full Text] [Related]
2. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
3. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.
Beck WT
J Natl Cancer Inst; 1989 Nov; 81(22):1683-5. PubMed ID: 2553990
[No Abstract] [Full Text] [Related]
4. Circumvention of atypical multidrug resistance with tumor necrosis factor.
Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
[TBL] [Abstract][Full Text] [Related]
5. Yeast as a genetic model system for studying topoisomerase inhibitors.
Nitiss JL
Adv Pharmacol; 1994; 29B():201-26. PubMed ID: 8996609
[No Abstract] [Full Text] [Related]
6. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
Davies SL; Bergh J; Harris AL; Hickson ID
Br J Cancer; 1997; 75(6):816-21. PubMed ID: 9062401
[TBL] [Abstract][Full Text] [Related]
7. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
Ishida R; Andoh T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
[TBL] [Abstract][Full Text] [Related]
8. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
Gudkov AV; Zelnick CR; Kazarov AR; Thimmapaya R; Suttle DP; Beck WT; Roninson IB
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3231-5. PubMed ID: 8386368
[TBL] [Abstract][Full Text] [Related]
9. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
10. Altered DNA topoisomerase II in multidrug resistance.
Beck WT; Danks MK; Wolverton JS; Granzen B; Chen M; Schmidt CA; Bugg BY; Friche E; Suttle DP
Cytotechnology; 1993; 11(2):115-9. PubMed ID: 7764055
[TBL] [Abstract][Full Text] [Related]
11. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
[TBL] [Abstract][Full Text] [Related]
12. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.
Beck WT; Danks MK; Wolverton JS; Chen M; Granzen B; Kim R; Suttle DP
Adv Pharmacol; 1994; 29B():145-69. PubMed ID: 8996606
[No Abstract] [Full Text] [Related]
13. Topoisomerase II in multiple drug resistance.
Hofmann GA; Mattern MR
Cytotechnology; 1993; 12(1-3):137-54. PubMed ID: 7765323
[TBL] [Abstract][Full Text] [Related]
14. Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
Nitiss JL; Nitiss KC
Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243
[No Abstract] [Full Text] [Related]
15. A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.
Blower TR; Bandak A; Lee ASY; Austin CA; Nitiss JL; Berger JM
Nucleic Acids Res; 2019 Sep; 47(15):8163-8179. PubMed ID: 31287876
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
Liu LF; D'Arpa P
Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
[No Abstract] [Full Text] [Related]
17. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
18. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation.
Madelaine I; Prost S; Naudin A; Riou G; Lavelle F; Riou JF
Biochem Pharmacol; 1993 Jan; 45(2):339-48. PubMed ID: 8382060
[TBL] [Abstract][Full Text] [Related]
19. Resistance to topoisomerase II poisons: is the answer in the promoter?
Kaufmann SH
Leuk Res; 1997; 21(11-12):1033-6. PubMed ID: 9444936
[No Abstract] [Full Text] [Related]
20. Alchemix, p53 and topoisomerase.
Grand RJ; Stewart GS
Aging (Albany NY); 2015 Sep; 7(9):601-2. PubMed ID: 26388618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
